| 70.08 -0.24 (-0.34%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 85.26 | 1-year : | 88.04 |
| Resists | First : | 73 | Second : | 75.37 |
| Pivot price | 70.47  |
|||
| Supports | First : | 69.15 | Second : | 57.53 |
| MAs | MA(5) : | 71.01 |
MA(20) : | 70.49 |
| MA(100) : | 71.62 |
MA(250) : | 73.01 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 47.2 |
D(3) : | 59.2 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 87.68 | Low : | 61.24 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AZN ] has closed above bottom band by 37.4%. Bollinger Bands are 53.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 70.78 - 71.22 | 71.22 - 71.53 |
| Low: | 68.8 - 69.36 | 69.36 - 69.75 |
| Close: | 69.35 - 70.16 | 70.16 - 70.74 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Wed, 16 Jul 2025
AstraZeneca’s Promising Phase II Study on AZD7798 for Crohn’s Disease - TipRanks
Wed, 16 Jul 2025
AstraZeneca’s Promising Update on AZD2936 for Advanced NSCLC - TipRanks
Wed, 16 Jul 2025
AstraZeneca’s New Study Targets COPD Burden in Egypt: What Investors Need to Know - The Globe and Mail
Wed, 16 Jul 2025
AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for SLE - The Globe and Mail
Tue, 15 Jul 2025
AstraZeneca PLC (AZN) Secures EU Approval for Imfinzi - Yahoo Finance
Mon, 14 Jul 2025
AstraZeneca’s Baxdrostat hits all Phase III endpoints, eyes 2025 filing | AZN SEC Filing - Form 6-K - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 3,100 (M) |
| Shares Float | 1,540 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 17 (%) |
| Shares Short | 7,450 (K) |
| Shares Short P.Month | 7,340 (K) |
| EPS | 2.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 26.47 |
| Profit Margin | 14.1 % |
| Operating Margin | 27.9 % |
| Return on Assets (ttm) | 8.1 % |
| Return on Equity (ttm) | 19.7 % |
| Qtrly Rev. Growth | 7.1 % |
| Gross Profit (p.s.) | 14.62 |
| Sales Per Share | 17.73 |
| EBITDA (p.s.) | 5.89 |
| Qtrly Earnings Growth | 33.5 % |
| Operating Cash Flow | 13,090 (M) |
| Levered Free Cash Flow | 9,350 (M) |
| PE Ratio | 28.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.64 |
| Price to Sales | 3.95 |
| Price to Cash Flow | 16.59 |
| Dividend | 1.04 |
| Forward Dividend | 0 |
| Dividend Yield | 1.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|